Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SII Inactivated Adjuvanted Polio Vaccine Phase III
NCT05163561Phase 3Completed
- Sponsor
- Serum Institute of India
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SII Inactivated Salk Polio Vaccine in poliomyelitis (4 arms), sponsored by Serum Institute of India. Primary endpoint: Percentage of participants with type-specific seroconversion. Started Jan 2022; status: completed.
02
Drugs
SII Inactivated Salk Polio Vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT05163561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163561.